Skip to main content

Johnson & Johnson Seeks Emergency Use Authorization For Its COVID Booster

Publish date:
Video Rating:
Video Duration:

Johnson & Johnson  (JNJ) - Get Free Report has submitted a request to the Food and Drug Administration (FDA) for emergency use authorization for its COVID-19 vaccine booster dose. 

On Tuesday, the company said it seeks approval of the booster shots for people above 18 years.

"Our clinical program has found that a booster of our COVID-19 vaccine increases levels of protection for those who have received our single-shot vaccine to 94 percent. We look forward to our discussions with the FDA and other health authorities to support their decisions regarding boosters," said Janssen Research & Development Head Mathai Mammen. "At the same time, we continue to recognize that a single-shot COVID-19 vaccine that provides strong and long-lasting protection remains a crucial component to vaccinating the global population." 

On September 23, the CDC endorsed Pfizer’s  (PFE) - Get Free Report COVID-19 booster shots for individuals aged 65+ and vulnerable populations.

Related: CDC Panel Green Lights Pfizer Booster for Individuals Ages 65+, Vulnerable Population

On September 27, U.S. President Biden received Pfizer’s booster shot.

Related Videos